Faisal Khurshid
Stock Analyst at Leerink Partners
(2.09)
# 2,877
Out of 4,944 analysts
22
Total ratings
47.06%
Success rate
-4.01%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $96.39 | +5.82% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $4.27 | +17.10% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.98 | +1.78% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $15.92 | +182.66% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.96 | +60.64% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.76 | +424.59% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.68 | +19.05% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $5.23 | +205.93% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $39.87 | +50.49% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $88.34 | -9.44% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.47 | +920.41% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $7.33 | -4.50% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.50 | +157.14% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $31.66 | -24.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.35 | +418.52% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.66 | +118.58% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.85 | +486.72% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.47 | +216.71% | 1 | Mar 21, 2023 |
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $96.39
Upside: +5.82%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $4.27
Upside: +17.10%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.98
Upside: +1.78%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $15.92
Upside: +182.66%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.96
Upside: +60.64%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.76
Upside: +424.59%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.68
Upside: +19.05%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $5.23
Upside: +205.93%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $39.87
Upside: +50.49%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $88.34
Upside: -9.44%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.47
Upside: +920.41%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $7.33
Upside: -4.50%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.50
Upside: +157.14%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $31.66
Upside: -24.18%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.35
Upside: +418.52%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.66
Upside: +118.58%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.85
Upside: +486.72%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.47
Upside: +216.71%